Published in Bone Marrow Transplant on May 04, 2009
Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol (2011) 1.17
NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant (2011) 0.91
Oral manifestations in transplant patients. Dent Res J (Isfahan) (2015) 0.91
NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. Biol Blood Marrow Transplant (2011) 0.83
Endocrine late effects after total body irradiation in patients who received hematopoietic cell transplantation during childhood: a retrospective study from a single institution. J Cancer Res Clin Oncol (2011) 0.83
Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up. Bone Marrow Transplant (2015) 0.78
The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant (2016) 0.77
Exploring the Content of Post-Traumatic Stress Symptoms among Parents after Paediatric Stem Cell Transplant. PLoS One (2015) 0.77
Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant (2015) 0.76
Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood. Children (Basel) (2015) 0.75
Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies. Sci Rep (2014) 0.75
Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT). Cancer Med (2016) 0.75
Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplant (2016) 0.75
Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol (2015) 0.75
Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant (2017) 0.75
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Inherited Bone Marrow Failure Syndromes (IBMFS): Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. Biol Blood Marrow Transplant (2017) 0.75
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Alternative therapies for the treatment of childhood cancer. N Engl J Med (1998) 2.82
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
Developing evidence-based guidelines for referral for short stature. Arch Dis Child (2007) 2.49
Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost (2007) 1.67
X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res (1995) 1.65
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer (2004) 1.58
A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J Clin Endocrinol Metab (2001) 1.51
Choroid plexus tumours. Br J Cancer (2002) 1.50
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost (2008) 1.48
Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost (2008) 1.45
Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost (2014) 1.43
Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart (2008) 1.42
Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients. Bone Marrow Transplant (2005) 1.41
[Three children with general malaise, fever, weight loss and cervical lymphadenopathy]. Ned Tijdschr Geneeskd (2004) 1.40
Pubertal development in The Netherlands 1965-1997. Pediatr Res (2001) 1.40
[Cardiovascular risk factors. II. Signs of vascular damage: practical implications]. Ned Tijdschr Geneeskd (2002) 1.39
[Defecation complaints after hysterectomy because of a benign condition are rare; a prospective study]. Ned Tijdschr Geneeskd (2007) 1.39
Langerhans cell histiocytosis--clinical and epidemiological aspects. Br J Cancer Suppl (1994) 1.38
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer (2009) 1.35
The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am (1998) 1.28
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia (2002) 1.27
Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res (1995) 1.24
Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab (2001) 1.22
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant (2010) 1.20
Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia (2002) 1.20
Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia (2005) 1.19
Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol (2006) 1.17
Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol (1999) 1.14
How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more! Bone Marrow Transplant (2005) 1.11
Radiation therapy and survival in choroid plexus carcinoma. Lancet (1999) 1.11
Reconciling animal and human data in a cancer risk assessment of acrylonitrile. Scand J Work Environ Health (2001) 1.11
Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am (1998) 1.08
Familial clustering of Langerhans cell histiocytosis. Br J Haematol (1999) 1.06
Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2007) 1.05
The IGSF1 deficiency syndrome: characteristics of male and female patients. J Clin Endocrinol Metab (2013) 1.05
Short stature and the probability of coeliac disease, in the absence of gastrointestinal symptoms. Arch Dis Child (2004) 1.04
Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant (2005) 1.02
Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine (2004) 1.02
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost (2013) 1.01
Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol (2005) 1.01
PCR-mediated genotyping of Candida albicans strains from bone marrow transplant patients. Bone Marrow Transplant (1994) 1.00
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia (2010) 1.00
Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant (2004) 0.99
The contribution of hysterectomy to the occurrence of urge and stress urinary incontinence symptoms. BJOG (2002) 0.98
Red-blood-cell alloimmunization and number of red-blood-cell transfusions. Vox Sang (2011) 0.98
A randomized comparison of post-operative pain, quality of life, and physical performance during the first 6 weeks after abdominal or vaginal surgical correction of descensus uteri. Neurourol Urodyn (2005) 0.98
Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr (2001) 0.97
Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Dutch Growth Hormone Working Group. Horm Res (1995) 0.96
Acute GvHD: pathogenesis and classification. Bone Marrow Transplant (2008) 0.96
Does mode of hysterectomy influence micturition and defecation? Acta Obstet Gynecol Scand (2001) 0.96
Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways. Br J Cancer (2009) 0.95
Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol (2001) 0.95
Growth monitoring and diagnostic work-up of short stature: an international inventorization. J Pediatr Endocrinol Metab (2005) 0.94
A controlled trial of methionyl growth hormone therapy in prepubertal children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group. Acta Paediatr Scand (1989) 0.94
Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch Dis Child (2002) 0.93
The contribution of benzene to smoking-induced leukemia. Environ Health Perspect (2000) 0.93
Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group. Clin Endocrinol (Oxf) (1995) 0.92
Mutagenicity of derivatives and metabolites of 1-nitropyrene: activation by rat liver S9 and bacterial enzymes. Mutat Res (1985) 0.92
Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia (2003) 0.92
Papillary meningioma with pleural metastasis: case report and literature review. Acta Neurol Scand (2000) 0.92
Dose-response relation between acrylamide and pancreatic cancer. Occup Environ Med (2001) 0.92
Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant (2005) 0.91
Bioassay-directed fractionation of 1-nitropyrene metabolites: generation of mutagrams by coupling reverse-phase HPLC with microsuspension mutagenicity assays. Mutagenesis (1990) 0.91
Inhibition of Gsk3β in cartilage induces osteoarthritic features through activation of the canonical Wnt signaling pathway. Osteoarthritis Cartilage (2011) 0.90
IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome. Neurology (2000) 0.90
Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia (2003) 0.90
Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia (2001) 0.89
Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur J Pediatr (2000) 0.89
Managing a dual role--experiences and coping strategies of parents donating haploidentical G-CSF mobilized peripheral blood stem cells to their children. Psychooncology (2010) 0.89
Growth hormone treatment in Turner syndrome accelerates growth and skeletal maturation. Dutch Growth Hormone Working Group. Eur J Pediatr (1992) 0.89
Significance of amplified fragment length polymorphism in identification and epidemiological examination of Candida species colonization in children undergoing allogeneic stem cell transplantation. J Clin Microbiol (2004) 0.89
Screening for coeliac disease in Dutch children with associated diseases. Acta Paediatr Suppl (1996) 0.88
ABO incompatible stem cell transplantation in children does not influence outcome. Pediatr Blood Cancer (2007) 0.88
Genetic analysis of short children with apparent growth hormone insensitivity. Horm Res Paediatr (2012) 0.88
Membrane sweeping and prevention of post-term pregnancy in low-risk pregnancies: a randomised controlled trial. BJOG (2006) 0.88
Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia (2005) 0.88
Binding of 1-nitro[14C]pyrene to DNA and protein in cultured lung macrophages and respiratory tissues. Cancer Lett (1983) 0.87
Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer (1997) 0.87
Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab (2013) 0.87
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant (2005) 0.87
Final height and hormonal function after bone marrow transplantation in children. J Pediatr (1996) 0.87
Short stature associated with a novel heterozygous mutation in the insulin-like growth factor 1 gene. J Clin Endocrinol Metab (2010) 0.87
Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia (2001) 0.87
The laser lightning rod system: thunderstorm domestication. Appl Opt (1974) 0.86
Metabolism of 1-nitro[14C]pyrene in vivo in the rat and mutagenicity of urinary metabolites. Carcinogenesis (1984) 0.86
Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia (2002) 0.85
Risk Factors for Alloimmunisation after red blood Cell Transfusions (R-FACT): a case cohort study. BMJ Open (2012) 0.85
Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford) (2004) 0.85
Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab (2000) 0.85
Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thromb Haemost (2000) 0.85
Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr (1997) 0.85
Early puberty in adopted children. Horm Res (2002) 0.85